The optimized ThrCo formulation and its immune-cell, repeat-dose and tumour-model results are presented separately from the earlier screening mixtures.
Reported performance refers to the complete research formulation and the stated experimental model.
Formulation components and molecular-weight conversion
ALC-0315/PyCB/DSPC = 35.6:44.4:20 mol%. Source: Supplementary Materials, optimized ThrCo LNP composition (p. 3). This formulation contains neither cholesterol nor PEG lipid. N/P and lipid:RNA mass ratio were not established; neither is inferred from the molar composition.
Component mass calculator
Prefilled proportions follow the source specified above. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.
Component
MW
Molar ratio
Mass (mg)
Mass %
ALC-0315
PyCB lipid
DSPC
Formulation selection and particle measurements
Experiment / parameter
Study conditions
Result / interpretation
Optimized composition
Three-component ThrCo LNP
35.6:44.4:20 mol%; use this final composition rather than ambiguous labels in the earlier screen.
Size, PDI and loading
Main Fig. 2; Supplementary Fig. S3
Comparative particle and encapsulation data are plotted. Exact final values are not transcribed from graph heights.
The authors describe this as a BNT162b2 LNP comparator; it is a laboratory formulation and is not the licensed vaccine product.
Splenic expression and cell delivery
Experiment / parameter
Study conditions
Result / interpretation
Luciferase expression
IV mouse reporter experiments; main Fig. 2 and Fig. S6
Authors report 4.5-fold higher splenic signal than the laboratory ALC-0315 comparator and >40-fold higher signal than the 18PA formulation.
Benchmark imaging conditions
Supplementary Fig. S6
0.25 mg/kg luciferase mRNA; imaging 6 h after IV administration.
Functional reporter delivery
Cre mRNA in Ai14 reporter mice; main Fig. 3
Splenic dendritic cells and macrophages showed reporter activation. This is Cre-mediated recombination, not a CAR-T or Cas9 editing result.
Antigen response and repeat administration
Experiment / parameter
Study conditions
Result / interpretation
Antigen-specific CD8 T cells
OVA mRNA, 5 µg/mouse IV on days 0, 7 and 14; assessed day 17; n = 3
Tetramer-positive CD8 T cells: 9.06% for ThrCo, 3.96% for the laboratory comparator and 0.57% for PBS (Fig. 4D,E).
Repeated delivery
Two weekly EGFP-mRNA doses followed by luciferase mRNA; 5 µg/mouse; final imaging at 24 h
Splenic expression was better retained than with the PEG-containing comparator (Fig. 4F–I). This does not establish indefinite repeat-dose performance.
Tumour-model evidence
Experiment / parameter
Study conditions
Result / interpretation
B16F10-OVA lung metastasis model
15 µg OVA mRNA/mouse on days 1, 6 and 11; endpoint day 21
The ThrCo group had no detectable lung nodules at the reported endpoint (Fig. 5A–C).
Interpretation
Antigen-defined mouse tumour model
The result is specific to this vaccination schedule and model; it is not evidence of universal tumour eradication or human efficacy.
Tolerability and storage
Experiment / parameter
Study conditions
Result / interpretation
Liver chemistry
IV mRNA at 1 or 5 mg/kg; 24 h; Fig. 2N–Q
ALT/AST were evaluated; no significant elevation was reported at 1 mg/kg. The higher-dose comparison does not establish chronic safety.
Hemolysis
Main Fig. 3P,Q
The formulation showed low hemolysis under the tested physiological-pH conditions; this endpoint does not replace systemic toxicology.
Short-term storage
Supplementary Fig. S5D–G
Reporter activity was evaluated after 4°C for 48 h, −80°C for one week and 37°C for 24 h. These are formulation experiments, not the isolated lipid shelf life.